PRESS AND MARKEY SURVEY REVIEW

fountain-pen-442066 1280






6

 Non Alcoholic Fatty Liver Disease (NAFLD) et la Non Alcoholic Steato-Hepatitis (NASH) des pathologies de système : revue pour le réanimateur




Setting The Pace In The Race To Treat NASH

Posted by Rosana Kapeller 



Pivotal late-stage study of GENFIT's NASH candidate to commence this quarter By: Douglas W. House



Logribel Biostocks

Long only, biotech, micro-cap, deep value

Phase 3 NASH Trials: Genfit's Drug Will Beat Intercept's OCA To Market




Long only, biotech, micro-cap, deep value


Intercept: What We Learn From OCA's Failure In Japan Phase 2 NASH Trial



logo


Global NASH (Non –Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030)
(By Region, By Drugs – Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)



logo


Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunity in Various Geographies



NASH IS THE 21ST CENTURY’S LOOMING PUBLIC HEALTH THREAT

BY  ON 1/30/16 AT 2:50 PM




EASL NEWS on twitter during the Liver congress :

Actions de l'utilisateur

Abonné 

Henry E. Chang

@HenryEChang 

 Twitter Ambassador | Former Executive Director  & VP of Impact Initiatives  |  …


  1.   et 1 autre ont Retweeté

 23 hil y a 23 heures

Metabolic wrapup highlights target-based drugs in development for NAFLD/NASH


 16 avr.

Elafibranor shows high histological & metabolic efficacy in NASH eligible for pharmacotherapy


 16 avr.

Gilead press release from includes progress on Nimbus' ACC inhibitor NDI-010976 for NASH et al.


 16 avr.

Gilead announces new data evaluating investigational therapies for treatment of ,


 16 avr.

Karin: How do ROS loose the ability to induce cell death and allow for liver development in ?


  ont Retweeté

 16 avr.

Okim59 a retweeté EASL Education

Genfit.. Non-invasive method for diagnosis by Dr. Arun Sanyal


@EASLedu

Non-invasive method for diagnosis by Dr. Sanyal on Community Portal

 15 avr.Barcelona, Spain

Did u see the booth at the in Barcelona


 15 avr.

Dr. Alonso: Specific serum metabolic patterns reflecting each NASH subtype , type 3 mainly polyunsaturated fatty acids


 15 avr.

Strong efficacy of Elafibranor in severe NASH associated w/ strong reduction of cardiometablic risk, ePoster FRI-339


 15 avr.

Dr. C. Alonso: Why subtypes of : Identification of metabolic signatures could help understand


 15 avr.

GS-9674, FXR agonist, reduces steatohepatitis in NASH mouse model, currently in PI


 15 avr.

Nimbus Phase-1 SAD data for NDI-010976 (ACC inhibitor for NASH) presented at for first time.


 15 avr.

how do you stage NAFLD / NASH? Most use Fibroscan


 15 avr.

Miss NASH? Well, Answering Unmet PBC Need today 6:30


 15 avr.

Genfit .poster Friday Francque Majd


 14 avr.

Gilead is presenting results from studies of investigational compounds for the treatment of NASH at


 14 avr.

presents our NASH clinical data at (Ph1a poster Fri, Ph1b data oral presentation Saturday)


 14 avr.

NASH ePoster session starts now. FXR agonists up first.



 14 avr.

NASH symposium, Pr. Ratziu: Case study: a woman with insidious progression of NASH


 14 avr.

NASH symposium, NASH: Optimizing therapy for progressive disease – Organized by GENFIT:

 13 avr.

Registration for Understanding the Role of Evolving Targets in NASH is now open! North Entrance, Hall 8, Rm B3

 13 avr.

Check out 's presentation on and 's on hepatic encephalopathy this evening


 13 avr.

GENFIT ~ NASH Symposium Vlad D.Ratziu : What New Therapies Are on the Horizon; Efficacy and Safety Profiles


 13 avr.

Dr. Shalapour: Serum IgA correlates with fibrosis in human and mouse NASH/NAFLD


 13 avr.

Dr. Harrisson: summarizing slide on Pathogenesis of NAFLD/NASH


 12 avr.

Non-invasive method for diagnosis by Dr. Sanyal on Community Portal


  1.  17 hil y a 17 heures

Thank you for this great . The Swiss Liver Center looks forward to joining


 21 hil y a 21 heures

In great company; top influencers of




 16 avr.

Many Ways, One Aim: Beating Liver Disease.



 16 avr.

Good morning attendees! Wishing you all a fruitful day 4!

 15 avr.

Great algorithm for non-invasive NAFLD risk stratification



History in the making! Elimination statement signed and shared with WHO



 14 avr.

What a brilliant idea to make the long hallway an art exhibition! Well done art


  et 1 autre ont Retweeté

 14 avr.

Come and pick EASL last issues and 's available Booth Hall 8.0



 13 avr.

Excellent review on dysbiosis and liver disease by Svegliati-Baroni at Basic Science Seminar!



 13 avr.Barcelona, Spain

the version of dejeuner sur l'herbe





---------------------------------------------




NEW

A very good  NASH drugs pipe overview in chinese is here

非酒精性脂肪性肝炎(NASH)药物研发管线概述



A very good PBC and NASH trials presentation is here





The full publication of GOLDEN results in Gastroenterology

250927covertif







WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016